dna-testing
(4)
The Company That Turned 30 Billion Old Documents Into Your Family Story
It sells subscriptions to the past. With 30 billion records, the largest consumer DNA database around, and a growing stack of AI, Ancestry has quietly become one of the most durable businesses in consumer tech.
Imagene Labs
Imagene Labs is a Singapore-based health-tech company that runs an enterprise-grade, cloud-based B2B genetic analytics platform. Using patented ancestry-based genetic risk analytics and ethnically-relevant reference datasets, it turns a simple saliva sample into DNA insights that fitness, beauty, nutrition and healthcare brands use to build personalized products and services. Its consumer-facing brand, Ori, packages these insights into fitness, skincare and nutrition DNA tests for the Asian market and beyond.
Nucleus Genomics
Nucleus Genomics is a New York-based consumer genomics company that sells a $399 at-home, clinical-grade whole-genome sequencing kit and a software platform that turns a person's full DNA sequence into readable reports on disease risk, carrier status, traits, and longevity. Founded in 2021 by Thiel Fellow Kian Sadeghi, Nucleus pairs whole-genome data with polygenic risk scores and lifestyle inputs to estimate risk for common, complex conditions. In 2025 it expanded into reproductive products - carrier screening, partner DNA alignment, and a controversial embryo-ranking tool, Nucleus Embryo - that put the company at the center of a public debate over the science and ethics of genetic selection.
Kian Sadeghi
Kian Sadeghi is the founder and CEO of Nucleus Genomics, a New York biotech building consumer whole-genome sequencing that aims to put your DNA in your pocket. He dropped out of the University of Pennsylvania at 20, taught himself genetics across 18 notebooks in a Brooklyn year he hid from his parents, won a Thiel Fellowship, and raised roughly $32 million from Peter Thiel, Alexis Ohanian's Seven Seven Six, Balaji Srinivasan and Founders Fund. His mission traces to a cousin who died young of a suspected heart-rhythm disorder, and his blunt embrace of 'genetic optimization' has made him one of the most debated young founders in biotech.